middle.news
European Commission Approves DAYBU for Rett Syndrome, Unlocking Milestone Payments for Neuren
8:31am on Tuesday 25th of August, 2026 AEST
•
Pharmaceuticals
Read Story
European Commission Approves DAYBU for Rett Syndrome, Unlocking Milestone Payments for Neuren
8:31am on Tuesday 25th of August, 2026 AEST
Key Points
DAYBU gains first EU marketing authorisation for Rett syndrome
Approval covers all 27 EU states plus Iceland, Liechtenstein, Norway
Neuren to receive US$35 million on first sale plus up to US$170 million milestones
Commercial launch in Germany expected early Q4 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE